Reaction
Relapsing Multiple Sclerosis reporting signals
As of the last recalculation, Relapsing Multiple Sclerosis appears in 302 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is OCRELIZUMAB (PRR 202.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ocrelizumab | 114 | 202.9 | 203.3 |
| Ofatumumab | 24 | 54.0 | 54.0 |
| Botulinum Toxin Type A | 9 | 51.5 | 51.5 |
| Diroximel Fumarate | 8 | 47.5 | 47.5 |
| Siponimod | 6 | 47.3 | 47.3 |
| Fingolimod Hcl | 34 | 30.4 | 30.4 |
| Interferon Beta-1B | 8 | 29.5 | 29.5 |
| Teriflunomide | 17 | 27.4 | 27.4 |
| Glatiramer Acetate | 22 | 27.3 | 27.3 |
| Dimethyl Fumarate | 31 | 19.2 | 19.2 |